BioMarin Pharmaceuticals
BMRN
BMRN
426 hedge funds and large institutions have $15.6B invested in BioMarin Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 161 increasing their positions, 149 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
5% more capital invested
Capital invested by funds: $14.8B → $15.6B (+$725M)
0.46% more ownership
Funds ownership: 97.8% → 98.26% (+0.46%)
13% less call options, than puts
Call options by funds: $84.4M | Put options by funds: $97.6M
Holders
426
Holding in Top 10
14
Calls
$84.4M
Puts
$97.6M
Top Buyers
| 1 | +$304M | |
| 2 | +$99.8M | |
| 3 | +$80.1M | |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
+$79.5M |
| 5 |
UIM
USS Investment Management
London,
United Kingdom
|
+$67.5M |
Top Sellers
| 1 | -$75.4M | |
| 2 | -$70.2M | |
| 3 | -$67.6M | |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$61M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$56M |